A discussion about the power you have in political advocacy at the federal, state and local levels. One voice – yours! – makes a world of difference …
Friends of Cancer Research & the Brookings Institute:
November 14, 2012 – 8:30am- 3:00pm – The Washington Marriott – Washington, DC
Morning Keynote: Harold Varmus, M.D., Director, National Cancer Institute
Afternoon Keynote: Margaret Hamburg, M.D., Commissioner, U.S. Food and Drug Administration
New Legislation Would Provide Exclusivity Add-on for Significant Drug Combinations
By Kurt R. Karst, FDA Law Blog
Legislation co-sponsored by Representatives Brian Bilbray (R-CA), Carolyn Maloney (D-NY) and Rosa DeLauro (D-CT), and supported by the Melanoma Research Foundation, seeks to encourge the development of so-called “significant drug combinations” by offering the carrot of an extension of marketing exclusivity.
Bloomberg News: By Anna Edney on October 11, 2012
Obesity treatments, life-saving antibiotics and other drugs deemed to offer societal benefit despite their risks may get speedier U.S. approvals under plans being discussed to better balance innovation and safety.
As part of the performance commitments of the fifth authorization of the Prescription Drug User Fee Act (PDUFA V), FDA has published a notice in the Federal Register related to Patient-Focused Drug Development, an initiative that provides for a more systematic approach to obtaining the patient perspective on certain disease areas in PDUFA V.
Saving time in medical research means saving lives. That’s the theme of a new social media campaign by FasterCures, designed to elevate the profile of medical research on the national agenda and underscore the toll of a slow, inefficient research system on every life. Through personal stories and compelling graphics, Time=Lives explains why medical research matters.
Legislation co-sponsored by Representatives Brian Bilbray (R-CA), Carolyn Maloney (D-NY) and Rosa DeLauro (D-CT), and supported by the Melanoma Research Foundation, seeks to encourage the development of so-called “significant drug combinations” by offering the carrot of an extension of marketing exclusivity.
By Laura Welch
I am a 33-year-old mother of a 2-year-old boy and wife to a wonderful US Soldier. In July 2011 we moved from Seattle to DC. Hello sunshine!
On August 18, 2011, I was diagnosed with Epitheliod Sarcoma (ES), a rare and aggressive form of cancer. I did what anyone in this day and age would do; I consulted the bible that is Google! The prognosis was bleak, to put it mildly. However, I am of the mindset that if this disease is so rare that it has little data available, I will make my own data and try not to dwell on the figures in front of me.
ACT UP and their colleagues fought for nine years before winning life-saving medications. They organized a mass movement, they took to the streets, they made art, they made noise, they made a difference. Their tools included clear demands, arresting graphics, media savvy, and an ability to learn from their mistakes and refine their strategies. And a sense of humor, when appropriate, in combination with their urgent and ethical message.
The POLITICO Pro Health care team takes an in-depth look at the future and policies of the FDA. Special guests include: Friends of Cancer Research’s Dr. Jeff Allen; The Pew Charitable Health Group’s Allan Coukell; Biotechnology Industry Organization’s Sara Radcliffe and the FDA’s Dr. Janet Woodcock.